Live Oak Bancshares, Inc. Announces Date of Third Quarter 2025 Financial Results WILMINGTON, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares, Inc. (NYSE: LOB) today announced that it will report its third quarter 2025 financial results after U.S. financial markets close on Wednesday, October 22, 2025. In conjunction with this announcement, Live Oak will host a conference call to discuss the company's financial results and business outlook on Thursday, October 23, 2025, at 9:00 a.m. ET. The call will be accessible by telephone and webcast using Conference ID: 72227. A supplem...
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced participation in the AASLD Liver Meeting 2025. The company will deliver two presentations, including one oral and one poster presentation, highlighting data from the NAVIGATE trial assessing belapectin for the treatment of MASH cirrhosis. The meeting will be held November 7-...
Live Oak Bank Leads Nation in SBA 7(a) Lending Activity WILMINGTON, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Live Oak Bank has been named the most active SBA 7(a) lender by dollar amount by the U.S. Small Business Administration. The results are posted to the and display the country’s top SBA 7(a) lenders by dollar amount and loan volume for the administration’s 2025 fiscal year, which ended September 30, 2025. “The SBA 7(a) program continues to be a vital resource for American small business owners seeking access to capital,” said James S. (Chip) Mahan III, Chairman and CEO of Live Oak...
A director at Phibro Animal Health Corp sold 20,664 shares at 40.380USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York, NY. H.C. Wainwright 27th Annual Global Investment ConferenceCompany presentation: September 8, 2025, at 1:00 PM ET. Webcast: The live and archived webcast will also be available on the pa...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Live Oak Ventures Participates in Financing of Cascading AI, Inc. WILMINGTON, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Live Oak Ventures, the investment arm of Live Oak Bancshares, Inc., has announced an investment in Cascading AI, Inc. (Casca), a loan application and origination platform using responsible artificial intelligence. Live Oak Bank is working as a design partner with Casca to automate its Live Oak® Express loan process and plans to expand Casca across the franchise to accelerate workflows and ultimately provide an exceptional banking experience to customers. “Businesses trus...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and six months ended June 30, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “We are encouraged by the continued analysis of data from our NAVIGATE trial , which further supports the clinical profile of belapectin in patient...
Live Oak Bancshares Announces Appointment of Jeffrey W. Lunsford to Board of Directors WILMINGTON, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares announced today the appointment of Jeffrey W. Lunsford to its board of directors. Lunsford has also been appointed to the board of directors of Live Oak Bank. “As a successful entrepreneur and financial technology expert, Jeff brings a deep level of technical expertise to our board,” said Live Oak Bancshares Chairman and CEO James S. (Chip) Mahan III. “His skill sets are an excellent match for Live Oak as we continue to redefine wh...
Live Oak Bancshares, Inc. Closes Depositary Share Offering WILMINGTON, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares, Inc. (NYSE: LOB) (“Live Oak” or the “Company”) announced the closing of its previously announced underwritten offering of 4,000,000 depositary shares, each representing a 1/40th interest in a share of its 8.375% Fixed Rate Series A Non-Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock”), with a liquidation preference of $25 per depositary share. As a result of the public offering, Live Oak received proceeds of approximately $96,150,000, net ...
Live Oak Bancshares, Inc. Prices Depositary Share Offering WILMINGTON, N.C., July 28, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares, Inc. (NYSE: LOB) (“Live Oak” or the “Company”) announced the pricing of an underwritten offering of 4,000,000 depositary shares, each representing a 1/40th ownership interest in a share of 8.375% Fixed Rate Series A Non-Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock”), with a liquidation preference of $25 per depositary share. When, as and if declared by the board of directors of Live Oak, dividends will be payable on the Series A Prefer...
Live Oak Bancshares, Inc. Reports Second Quarter 2025 Results WILMINGTON, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares, Inc. (NYSE: LOB) (“Live Oak” or “the Company”) today reported second quarter of 2025 net income attributable to the Company of $23.4 million, or $0.51 per diluted share. Live Oak’s performance in the quarter, compared to the first quarter of 2025, includes these notable items: Record second quarter production of $1.53 billion accompanied by strong deposit growth of $198.8 million, with total assets growing by 1.7% to $13.83 billionNet interest income inc...
A director at Western Asset High Income Opportunity Fund Inc maiden bought 10,000 shares at 4.018USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.